Merck Management

Management criteria checks 1/4

Merck's CEO is Rob Davis, appointed in Apr 2021, has a tenure of 1.5 years. total yearly compensation is $13.72M, comprised of 9.6% salary and 90.4% bonuses, including company stock and options. directly owns 0.01% of the company’s shares, worth €21.74M. The average tenure of the management team and the board of directors is 1.6 years and 5.8 years respectively.

Key information

Rob Davis

Chief executive officer

US$13.7m

Total compensation

CEO salary percentage	9.6%
CEO tenure	1.5yrs
CEO ownership	0.01%
Management average tenure	1.6yrs
Board average tenure	5.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Rob Davis's remuneration changed compared to Merck's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2022	n/a	n/a	US$17b
Mar 31 2022	n/a	n/a	US$14b
Dec 31 2021	US$14m	US$1m	US$12b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$4b
Mar 31 2021	n/a	n/a	US$5b
Dec 31 2020	US$7m	US$1m	US$5b
Sep 30 2020	n/a	n/a	US$9b
Jun 30 2020	n/a	n/a	US$9b
Mar 31 2020	n/a	n/a	US$9b
Dec 31 2019	US$8m	US$1m	US$6b
Sep 30 2019	n/a	n/a	US$9b
Jun 30 2019	n/a	n/a	US$9b
Mar 31 2019	n/a	n/a	US$8b
Dec 31 2018	US$7m	US$1m	US$6b
Sep 30 2018	n/a	n/a	US$3b
Jun 30 2018	n/a	n/a	US$1b
Mar 31 2018	n/a	n/a	US$2b
Dec 31 2017	US$6m	US$1m	US$2b
Sep 30 2017	n/a	n/a	US$3b
Jun 30 2017	n/a	n/a	US$5b
Mar 31 2017	n/a	n/a	US$4b
Dec 31 2016	US$8m	US$992k	US$4b
Sep 30 2016	n/a	n/a	US$5b
Jun 30 2016	n/a	n/a	US$5b
Mar 31 2016	n/a	n/a	US$5b
Dec 31 2015	US$7m	US$964k	US$4b

Compensation vs Market: Rob's total compensation ($USD13.72M) is above average for companies of similar size in the BG market ($USD4.12M).

Compensation vs Earnings: Rob's compensation has increased by more than 20% in the past year.

CEO

Rob Davis (55 yo)

1.5yrs

Tenure

US$13,722,121

Compensation

Mr. Robert M. Davis, also known as Rob, J.D., is Chief Executive Officer and Director at Merck & Co., Inc. since July 1, 2021. He has been President for Merck & Co., Inc. (“Merck”) since April 01, 2021 and...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Kenneth Frazier	Executive Chairman	11.8yrs	US$15.20m	0.028% $ 62.4m
Robert Davis	President	1.5yrs	US$13.72m	0.0098% $ 21.7m
Caroline Litchfield	Executive VP & CFO	1.5yrs	US$4.22m	0.0011% $ 2.4m
Richard DeLuca	Executive VP & President of Merck Animal Health	11.1yrs	US$6.84m	0.0054% $ 11.9m
Dean Li	Executive VP & President of Merck Research Laboratories	1.8yrs	US$5.48m	0.00065% $ 1.4m
David Williams	Executive VP and Chief Information & Digital Officer	no data	no data	0.00037% $ 823.2k
Peter Dannenbaum	Vice President of Investor Relations	3.2yrs	no data	no data
Jennifer Zachary	Executive VP & General Counsel	4.5yrs	US$4.56m	0.0021% $ 4.7m
Lisa LeCointe-Cephas	Senior VP and Chief Ethics & Compliance Officer	1.5yrs	no data	0.00014% $ 311.5k
Jennifer Mauer	Vice President of Global Communications	no data	no data	no data
Cristal Downing	Executive VP and Chief Communications & Public Affairs Officer	1.2yrs	no data	no data
Steven Mizell	Executive VP & Chief Human Resources Officer	5.8yrs	no data	0.0016% $ 3.5m

1.6yrs

Average Tenure

54yo

Average Age

Experienced Management: 6MK's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Kenneth Frazier	Executive Chairman	11.8yrs	US$15.20m	0.028% $ 62.4m
Robert Davis	President	1.3yrs	US$13.72m	0.0098% $ 21.7m
Peter Wendell	Independent Director	19.1yrs	US$350.00k	0.000040% $ 89.0k
Pamela Craig	Independent Director	7.1yrs	US$375.00k	0.000070% $ 155.7k
Patricia Russo	Independent Director	27.1yrs	US$325.00k	0.00052% $ 1.2m
Thomas Glocer	Independent Lead Director	14.9yrs	US$350.00k	0.00020% $ 445.0k
Risa Lavizzo-Mourey	Independent Director	2.4yrs	US$324.50k	0.000040% $ 89.0k
Inge Thulin	Independent Director	4.6yrs	US$320.00k	0% $ 0
Kathy Warden	Independent Director	2.6yrs	US$330.00k	0.000020% $ 44.5k
Christine Seidman	Independent Director	2.6yrs	US$355.00k	0% $ 0
Paul Rothman	Independent Director	7.1yrs	US$371.67k	0% $ 0
Mary Coe	Independent Director	3.6yrs	US$330.00k	0% $ 0

5.8yrs

Average Tenure

66yo

Average Age

Experienced Board: 6MK's board of directors are considered experienced (5.8 years average tenure).

Merck Management

Management criteria checks 1/4

Key information

Recent management updates

Merck & Co., Inc., Annual General Meeting, May 28, 2024

Merck & Co., Inc. Announces Management Changes, Effective on December 4, 2023

Recent updates

Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA (pembrolizumab) Plus Chemotherapy

Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival as First-Line Treatment in Patients with HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Merck & Co., Inc. Provides Earnings Guidance for Full-Year 2024

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA®? (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer

European Commission Approves Merck’s Keytruda® (Pembrolizumab) Plus Chemotherapy

Merck Provides Update on Phase 3 Keylynk-006 Trial Evaluating Keytruda® (Pembrolizumab) Plus Maintenance Lynparza® (Olaparib) for Certain Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer

Merck Announces Positive Data on V116, Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults

Merck Announces its KEYTRUDA Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival Versus CRT Alone in Patients with Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Merck Announces Plans to Conduct Clinical Trials of A Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence

Merck & Co., Inc., Annual General Meeting, May 28, 2024

FDA Grants Priority Review to Merck's Application for Keytruda (Pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma

Health Canada Approves Keytruda® in Combination with Trastuzumab and Chemotherapy, as A First-Line Treatment for Patients with Locally Advanced Her2-Positive Gastric or Gastric or Gastroesophageal Junction Adenocarcinoma

Merck Announces Results from the Phase 3 AMBASSADOR (A031501/KeyNOTE-123 Trial Evaluating KEYTRUDA

Merck Declares Dividend for the Second Quarter of 2024, Payable on April 5, 2024

Merck & Co., Inc. Announces FDA Approves Merck's KEYTRUDA® (Pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients with FIGO 2014 Stage III-IVA Cervical Cancer

Merck Reportedly in Talks to Buy Harpoon Therapeutics

Merck & Co., Inc. Announces Phase 3 Trial Initiations for Four Investigational Candidates from Its Promising Hematology and Oncology Pipeline

FDA Grants Priority Review to Merck's New Biologics License Application for V116

Merck Announces FDA Approves Expanded Indication for KEYTRUDA (pembrolizumab) Plus Padcev for the First-Line Treatment of Adult Patients with Locally Advanced or Metastatic Urothelial Cancer

Merck and Moderna Initiates INTerpath-002, A Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with Keytruda® (Pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer

Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) (Lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer

Merck & Co., Inc. Announces Management Changes, Effective on December 4, 2023

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age